Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.68 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627269 | 0.96 | CCR2 (0.66) | CCR2KCNH2SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL13627434 | 0.90 | CCR2 (0.68) | CCR2KCNH2JAK1PIK3CDPIK3R1 | |
| SCHEMBL13627020 | 0.88 | CCR2 (0.66) | CCR2KCNH2 | |
| SCHEMBL13627436 | 0.86 | CCR2 (0.69) | CCR2KCNH2CHRM4PIK3CDPIK3R1 | |
| SCHEMBL13627090 | 0.86 | CCR2 (0.68) | CCR2KCNH2HCRTR1HCRTR2CHRM4 | |
| SCHEMBL13627071 | 0.84 | CCR2 (0.68) | CCR2KCNH2 | |
| SCHEMBL13627268 | 0.83 | CCR2 (0.53) | CCR2KCNH2CA12CA1CA2 | |
| SCHEMBL13627012 | 0.82 | CCR2 (0.66) | CCR2KCNH2 | |
| SCHEMBL13627175 | 0.82 | CCR2 (0.61) | CCR2KCNH2HCRTR1HCRTR2SYK | |
| SCHEMBL4338811 | 0.81 | CCR2 (1.00) | CCR2KCNH2SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | XUE CHU-BIAO | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CCR2 1/4885KCNH2 2769/4885SLC6A7 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.